Selpercatinib is a next-generation targeted therapy designed to inhibit RET fusions and mutations, used in advanced or metastatic RET fusion-positive NSCLC, with progression-free survival benefit, as shown in the clinical trial LIBRETTO-001 [1,4]. The gene discussed is RET; the disease is non-small cell lung carcinoma.